BMY ▼ -0.9% - Bristol-Myers Squibb Company $BMY Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ... Bristol Myers Squibb announced positive topline results from its Phase 2 QUINTESSENTIAL trial of arlocabtagene autoleucel, a potential first-in-class GPRC5D-directed CAR T cell therapy, though the stock declined 0.9% on the news. The positive trial data would typically be expected to support the stock, suggesting investors may have been pricing in the success or have concerns about other factors. 08-SEP-2026 06:59 AM ET